Prescribing information

A targeted treatment for immune thrombocytopenia (ITP) patients

REVOLADE acts in the bone marrow by mimicking the actions of thrombopoietin (TPO), the hormone responsible for stimulating platelet production1,2 

Unlike immunosuppressive therapies, REVOLADE acts specifically on the TPO receptor and does not interfere with normal immune function1–3


REVOLADE, unlike larger thrombopoietin receptor agonists (TPO-RAs):

Complements endogenous TPO activity1,2

Does not promote neutralising antibodies2

Mimics endogenous TPO with once-daily oral dosing1,2

REVOLADE’s TARGETED mechanism of action allows for platelet control without immunosuppression1–3

FCT, film-coated tablet; ITP, immune thrombocytopenia; TPO, thombopoietin; TPO-RA, thrombopoietin receptor agonist.
*The half-life of REVOLADE (~21–32 hours) relative to dosing frequency (every 24 hours) allows for steady drug levels, mimicking endogenous TPO.1,2
  1. REVOLADE FCT Summary of Product Characteristics.
  2. Kuter D. Int J Hematol. 2013;98:10–23.
  3. McCrae K. Cleve Clin J Med. 2011;78:358–373..
IE | May 2022 | 174745
Rate this content: 
No votes yet

Ask Speakers


Medical Information Request

Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: Adverse events could also be reported to Novartis preferably via or by email:[email protected] or by calling 01 2080 612.